

# Technology-based prescreening (BP devices, Fitbit etc., smartphone apps)

ESC Cardiovascular Workshop Amsterdam March 27th, 2017

Rolf Wachter, Göttingen



### **Conflict of Interest - Disclosure**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed

Affiliation/Financial Relationship	Company		
1. Honoraria for lectures	Bayer, Berlin Chemie, Boehringer Ingelheim, CVRx, Medtronic, Novartis,		
Pfizer, Servier			
2. Honoraria for advisory board activities	Boehringer Ingelheim, Novartis		
3. Participation in clinical trials	Bayer, Boston Scientific, Celladon, CVRx, Johnson & Johnson, Medtronic, Novartis, Pfizer, Servier		
4. Research funding 2020) au	BMBF (Kompetenznetz Herzinsuffizienz und DZHK), European Union (Horizon nd Boehringer Ingelheim		
5. Other	Ich habe 27 Slides, aber nur 12 Minuten Zeit		

#### **Devices available for prescreening**









#### Some general considerations

- 1. The yield of AF in patients with paroxysmal AF is mainly a function of time. The longer you look, the more you will find.
- 2. Most AF episodes are asymptomatic. So prescreening based on symptoms (e. g. prescreening triggered by the patient) will miss most of the episodes.
- 3. Prescreening has to be user-friendly. The typical AF patient is not a smartphone maniac.



#### **Zenicor Device**

records ECG for 30 seconds, can send data via mobile network




Figure 1. Example of thumb ECG registrations: Atrial Fibrillation above, Sinus Rhythm below.

N=606, Sensitivity 92 %, specificity 96 %

### iPhone based screening (e.g. Alive Cor)





#### Pulse waveform analysis




Algorithm based on analysis of RR intervals

Test Characteristics\* for our Arrhythmia Detection Algorithm in 104 Subjects with Atrial Fibrillation, 91 with Sinus Rhythm, 14 with Premature Atrial Contraction, and 16 with Premature Ventricular Contractions.

Algorithm	Sensitivity	Specificity	Accuracy
Atrial Fibrillation	0.970	0.935	0.951
Premature atrial Contraction	0.667	0.980	0.955
Premature ventricular contraction	0.733	0.976	0.960

## mydiagnoStick ———



## Comparison between single-lead ECG and modified BP monitors

BMJ Open Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors

Karen Kearley, Mary Selwood, Ann Van den Bruel, Matthew Thompson, David Mant, FD Richard Hobbs, David Fitzmaurice, Carl Heneghan








## Comparison between single-lead ECG and modified BP monitors

n=999* Prevalence 7.9%	WatchBP with AF indicator flash (95% CI)	Omron autoanalysis* (95% CI
Sensitivity (%)	94.9 (87.5 to 98.6)	98.7 (93.2 to100)
Specificity (%)	89.7 (87.5 to 91.6)	76.2 (73.3 to 78.9)
Positive likelihood ratio	9.2 (7.6 to 11.2)	4.15 (3.69 to 4.67)
Negative likelihood ratio	0.057 (0.022 to 0.15)	0.017 (0.0024 to 0.12)
Positive predictive value	44.1 (36.5 to 51.9)	26.3 (21.3 to 31.7)
Negative predictive value	99.5 (98.8 to 99.9)	99.9 (99.2 to 100)

WatchBP performs better than the single-lead ECG monitors as a triage test for identifying AF in primary care as it does not require any expertise for interpretation and their diagnostic performance is comparable.

#### AliveCor versus WatchBP



#### Test characteristics of different devices

Device	Method of interpretation	Sensitivity (%)	Specificity (%)	Reference
Pulse palpation		94 (84-97)	72 (69-75)	Cooke et al., 2006
Handheld single-lead ECGs				
AliveCor (Kardia) heart	Algorithm only (based on presence of P	98 (89-100)	97 (93-99)	Lau et al., 2013
monitor	wave and RR irregularity)			
Merlin ECG event	Cardiologist interpretation	93.9	90.1	Kearley et al., 2014
recorder				
Mydiagnostick	Algorithm only (based on RR irregularity)	94 (87–98)	93 (85–97)	Tieleman et al., 2014 Vaes et al., 2014
Omron HCG-801	Algorithm only (based on RR irregularity)	98.7 (93.2-100)	76.2 (73.3-78.9)	Kearley et al., 2014
Omron HCG-801	Cardiologist interpretation	94.4	94.6	Kearley et al., 2014
Zenicor EKG	Cardiologist interpretation	96	92	Doliwa et al., 2009
Modified Blood pressure	e monitors			
Microlife BPA 200 Plus	Algorithm only (based on pulse irregularity)	92	97	Marazzi et al., 2012
Microlife BPA 200	Algorithm only (based on pulse irregularity)	97 (81.4-100)	90 (83.8-94.2)	Wiesel et al., 2014
Omron M6	Algorithm only (based on pulse irregularity)	100	94	Marazzi et al., 2012
Omron M6 comfort	Algorithm only (based on pulse irregularity)	30 (15.4-49.1)	97 (92.5-99.2)	Wiesel et al., 2014
Microlife WatchBP	Algorithm only (based on pulse irregularity)	94.9 (87.5-98.6)	89.7 (87.5-91.6)	Kearley et al., 2014
Plethysmographs				
Finger probe	Algorithm only (based on pulse	100	91.9	Lewis et al., 2011
'al l	irregularity)	07.0	00 -	
iPhone photo-	Algorithm only (based on pulse	97.0	93.5	McManus et al., 2016
plethysmograph	irregularity)			

#### **Devices for PREscreening**

- 1. ECG diagnosis is always required for validation of AF diagnosis. No therapeutic actions (e. g. anticoagulation) can be taken prior to validation of the diagnosis
- 2. Handheld ECG devices with a verifiable ECG trace are preferred.

#### **Pitfalls**






False positive cases of the myDiagnostick rhythm stab

#### ECG tracings in different monitoring modalities






External
Event Recorder



Implantable Cardiac Monitor



#### A shift in paradigm for thinking about stroke

Retrospection (Cryptogenic stroke, ESUS) Why did this stroke happen? Can I find an explanation? Is it cryptogenic? Does it look embolic? Should I anticoagulate?

Cerebral events (stroke, TIA)

1st stroke

Prevent


2nd stroke

AF cluster

Look ahead (Find-AF randomised)

Time

Stroke patients have a high risk of underlying AF irrespective of stroke etiology and should be anticoagulated if AF is detected







#### **Find-AF randomised**




#### **Strokes**



#### **Primary Endpoint in Subgroups**



#### Candidats for prolonged monitoring in stroke







#### Own experience, Zenicor in Find-AF randomised

n=398 stroke patients, randomised to prolonged and enhanced monitoring or usual care

Prolonged and enhanced monitoring =  $3 \times 10$  day Holter ECG, evaluated in a dedicated core lab.

Patients not willing to have the second or third Holter ECG were offered a Zenicor device







#### **Compliance with Holter, alternative Zenicor**

	baseline	3-month-visit	6-month-visit
scheduled for Holter- ECG by study protocol	200	170	153
any prolonged study ECG-monitoring	199# (99.5 %)	128 (75.3 %)	116 (75.8 %)
study Holter-ECG monitoring	199# (99.5 %)	116 (68.2 %)	100 (65.3 %)
median duration of Holter-ECG (IQR)	9.5 d (8.0; 9.8 d)	9.6 d (8.6; 9.9 d)	9.6 d (8.2; 9.9 d)
thumb-sensor-ECG (Holter-ECG refused)	na	12 (7.1 %)	16 (10.4 %)

AF detected by thumb-sensor = 0

#### "Longest AF episode"





PI David Gladstone, Toronto Canada, n=822, NCT02392754

#### **Conclusion**

Devices that use algorithms to detect rhythm irregularity are mainly able to detect persistent and permanent AF. There is the risk of false positive results and ECG documentation is always necessary.

Handheld ECG devices with verifiable ECG tracing are preferred.

The duration of monitoring is the most important point